Tags Posts tagged with "Cannabis"

Cannabis

0 1090
marijuana

$UBQU Premieres New 24 Hour Interactive Customer Support Phone System

 

Ubiquitech Software Corp. ( OTC PINK : UBQU ), through its operating subsidiary HempLife Today™, is announcing the development and implementation of its new IVR (Interactive Voice Response), 24 hour toll-free customer support phone system, developed to improve customer support, customer satisfaction, and increase sales volume.

This new IVR system was developed using one of the most technologically advanced software applications in the industry, and will help the Company to better serve its daily increase of customers for its growing line of CannazALL™ CBD products derived from Hemp, by offering an easier way to learn more about the Company, the products, and to better speak to a specialist who can assist in taking an order.


Click Here Now To Read Full PR


7 Cannabis Company Developments to Highlight

This week was a busy week for cannabis stocks and this is important as it follows a couple rough weeks of trading. Some of the important develops we think investors should take note of, include…[continue reading]


Click Here Now To Read Full Article


#ICYMI: Will This Marijuana Stock See a Record Setting Year in 2017?

Among the many segments of the marijuana industry that we cover, CBD has taken on a big role not only for its biotech-based applications but also for its uses outside of the health sciences sector. And with the growth that the market as a whole could be set to see, CBD companies are definitely in the spotlight for the foreseeable future.

One Marijuana Stock that we’ve been reporting on since late last year has been Ubiquitech Software Corp (UBQU). Now don’t let the name fool you, this company, through its subsidiary HempLife Today™ is breaking barriers with its CBD brand while also hitting major milestones over the last year. What could be best of all is that 2017 could already have the stage set for yet another record setting period in (UBQU)’s company history.


Click Here Now To Read Full Article


 

Pursuant to an agreement between MAPH and Ubiquitech Software Corp., we were hired for a period beginning November 11 2016 and ending May 11, 2017 to publicly disseminate information about (UBQU) including on the Website and other media including Facebook and Twitter. We are being paid $0 (CASH) for or were paid “10 million” shares of restricted common shares. We may buy or sell additional shares of (UBQU) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER

0 3878
Marijuana Stocks

Marijuana Stocks, especially Cannabis Companies with strong ties to Biotech have been increasingly front and center on Wall Street’s main stage.  Marijuana Stocks and the Cannabis-Biotech sector continue to evolve and grow into the mainstream powerhouse we know it can and will be. We have identified a small Cannabis-Biotech start up that deserves your attention.

InMed Pharmaceuticals (IMLFF) is a Vancouver-based pre-clinical trial Cannabis-Biotech company that has not only developed a proprietary cannabinoid manufacturing system yet in the process created a highly sought after database, which has mapped the different compounds of cannabinoids to the various diseases that it can address.

This cannabinoid database was designed by (IMLFF) to assist them in their investigative studies and has currently become a core asset as other Cannabis Biotech companies have come knocking on their door willing to offer a hefty sum for this information. Most medical marijuana processors are using THC and CBD because they are easy to extract in large quantities, however there are more than 90 diverse cannabinoid structures that (IMLFF) has plugged into its system. The bioinformatics algorithm has taken those different compounds and screens them against approved drugs, diseases and genetic properties of diseases. It then selects specific cannabinoids that might help regulate that particular disease.

InMed Pharmaceuticals (IMLFF) has created this database “tool” & is saving time and money in the drug research process. It has already helped (IMLFF) to identify two treatments for rare diseases. One for a rare children’s skin disease called epidermolysis bullosa (EB) that has no approved treatments and the other for glaucoma. Chief Executive Officer Eric Adams said, “It’s a very devastating disease and we found out in early testing that this set of cannabinoids treat the major symptoms of this disease giving them a tremendous amount of relief, but it may also reverse the disease, which is something no one has really talked about before.”

Startup Cannabis-Biotechs like InMed Pharmaceuticals (IMLFF) will continue to grow as Marijuana Stocks / Sector continues to evolve into mainstream markets.

0 2274
marijuana_glaucoma

Research has shown that cannabinoids can alleviate glaucoma-related symptoms because they lower the intraocular pressure (IOP) and have neuroprotective actions. For example, in 1971, one of the first studies of its kind found ingestion of cannabis lowers IOP by 25 to 30%. Despite the findings from early research, very few ophthalmologists support the use of medical cannabis in patients with early to mid-stage glaucoma. The main issue ophthalmologists have with marijuana is that the potential adverse effects, particularly smoking cannabis, outweigh the short term benefits. For example, smoking can lead to unstable intraocular pressure, which heightens the risk of permanent vision loss.

Additionally, because its therapeutic effects on glaucoma are short-term, patients would have to consume marijuana frequently; once every three to four hours. Physicians claim that because glaucoma needs to be treated 24 hours per day, patients would need to consume marijuana six to eight times over the course of a day to achieve consistently decreased IOP levels. Such frequency is difficult to maintain and could heighten the risk of developing a marijuana use disorder. However, when it comes to late stage glaucoma, ophthalmologists are more inclined to embrace cannabis as a treatment. At the end stages of glaucoma, it is less about directly targeting the glaucoma and more about alleviating the accompanying symptoms.

Ophthalmologist Andrew Bainnson, MD stated, “We’ve known for some time that medical marijuana is very effective for treating nausea and pain, but not so much for glaucoma. However, there are some patients with end stage pain and nausea who may benefit [from medical marijuana], but not from the glaucoma point of view.” The body’s own internal cannabinoid system, called the endocannabinoid system (ECS), is one of our most important physiological systems. Nearly every aspect of our health including: inflammation, immune response, neuroprotection, pain modulation, are all dependent on the ECS. Given the vital role of the ECS, particularly in neuroprotection and inflammation, many scientists believe the development of cannabinoid-based medications may be useful in treating glaucoma.

1 2802

Cannabis shops and manufacturers have increasing concerns that the Trump Administration will enforce federal laws that restrict farming and selling the drug. This will reverse the president’s stance during his campaign and potentially overturn what has become a $7 billion industry. The worry was provoked by comments from White House spokesman Sean Spicer recently that the government would most likely boost its enforcement of drug laws.

Attorney General Jeff Sessions stated that he is “dubious” about the benefits of marijuana. He said, “Marijuana is against federal law, and that applies in states where they may have repealed their own anti-marijuana laws. So yes, we will enforce law in an appropriate way nationwide. It’s not possible for the federal government, of course, to take over everything the local police used to do in a state that’s legalized it. And I’m not in favor of legalization of marijuana. I think it’s a more dangerous drug than a lot of people realize.”

The comments have sparked worry with Chuck Smith, co-founder of Dixie Brands, a Denver-based company that manufactures topicals and edibles infused with THC, the active ingredient in cannabis. He founded the company in 2010 and now employs more than 100 people across Arizona, Colorado, California, and Nevada. Smith stated, “My concern right now for both the company and industry is just uncertainty. It’s hard to build an industry or a company when you don’t have clarity.”

The administration’s statements affected shares of Innovative Industrial Properties, which invests in cannabis-growing facilities and is one of the few publicly traded cannabis companies. Its stock price plummeted on the day of Spicer’s press conference and are down more than 13% since then. However, two other marijuana stocks, GW Pharmaceuticals and Cara Therapeutics, seem to have not been affected by the news.

Eight states now allow the use of cannabis recreationally, while more than two dozen states have legalized it for medical purposes. Twenty-one states have decriminalized cannabis. A recent Quinnipiac Poll found 71% of voters think the government should not restrict federal drug laws in states where marijuana is legal. Increasing acceptance has led to an jump in the market for cannabis in North America, with sales rising 34% to nearly $7 billion in 2016, according to Arcview Market Research. By 2021, the industry is likely to climb close to $22 billion.

Companies like Dixie Brands are charging that hike. The privately held company would not disclose current numbers, but in 2014 it was valued at $40 million. Smith said, “It’s hard for us to kind of go backwards. President Trump said he was going to allow this to be a state’s rights issue. We took him at his word.” Trump has sent mixed messages on cannabis. In the 1990s, he called for legalizing all drugs. On the campaign trail, he reiterated his support for medical cannabis and his deference to states to pass their own laws regulating the drug.

2 1807

The cannabis industry continues to face threats from Attorney General Jeff Sessions as his campaign against cannabis continued this week.

The AG recently said, “I realize this may be an unfashionable belief in a time of growing tolerance of drug use. But too many lives are at stake to worry about being fashionable. I reject the idea that America will be a better place if marijuana is sold in every corner store. And I am astonished to hear people suggest that we can solve our heroin crisis by legalizing marijuana – so people can trade one life-wrecking dependency for another that’s only slightly less awful. Our nation needs to say clearly once again that using drugs will destroy your life.”

Sessions should take a lesson from Joe Rogan. In a YouTube video, Rogan said, “The only reason why marijuana is illegal is because of economics. If marijuana was legal, it would cost pharmaceutical and alcohol companies billions of dollars every year. The Partnership for a Drug-Free America is funded by alcohol companies. Alcohol is a sanctioned drug”

Marijuana can treat several debilitating diseases and improve the daily life of millions of people around the world.

Ten illnesses that can be treated by marijuana

1.Marijuana can be used to treat and prevent glaucoma. According to the National Eye Institute, marijuana decreases the pressure inside the eye. “Studies in the early 1970s showed that marijuana, when smoked, lowered intraocular pressure (IOP) in people with normal pressure and those with glaucoma.”

2.Marijuana helps reverse the carcinogenic effects of tobacco and improves lung health. In January 2012, a study was published in Journal of the American Medical Association which said marijuana does not impair lung function and it can even increase lung capacity.

3.Marijuana can help control epileptic seizures. Charlotte Figi suffers from Dravet’s Syndrome and a strain of marijuana called “Charlotte’s Web” has decreased Charlotte’s seizures from 300 a week to just one every seven days.

4.Marijuana can decrease anxiety. In 2010, researchers at Harvard Medical School suggested that that some of marijuana’s benefits may be associated with reduced anxiety.

5.THC slows the progression of Alzheimer’s disease. A study led by Kim Janda of the Scripps Research Institute suggests that marijuana may be able to slow the progression of Alzheimer’s disease. In 2006, the study published in the journal of Molecular Pharmaceutics found that THC, the active chemical in marijuana, slows the formation of amyloid plaques by blocking the enzyme in the brain that makes them. These plaques are what kill brain cells and cause Alzheimer’s.

6.Marijuana helps ease the pain associated with multiple sclerosis. GW Pharmaceuticals (GWPH) has developed a drug derived from cannabis called Sativex which helps patients who suffer from multiple sclerosis.

7. Marijuana relieves arthritis discomfort. In 2011, researchers said that marijuana alleviates pain, reduces inflammation and promotes sleep, which may help relieve pain for people suffering from rheumatoid arthritis.

8.Marijuana can potentially eliminate Crohn’s disease. A study in Israel showed that smoking a joint significantly reduced Crohn’s disease symptoms in 10 out of 11 patients. Marijuana caused a complete remission in five of the patients.

9.Marijuana helps veterans suffering from PTSD. The Department of Health and Human Services recently signed off on a proposal to study marijuana’s potential as part of the treatment for veterans with post-traumatic stress disorder.

10.Marijuana reduces some of the pain and nausea from chemotherapy and stimulates appetite.

4 9671

By Jason Spatafora @WolfofWeedSt

“I fear the Greeks, even those bearing gifts.”- Virgil

The DEA’s recent cannabis research expansion is a Harry Houdini inspired smoke show of misdirection all to set up the next trick; there I said it. While some view it as a positive first step, I tend to think it served a very deliberate function. Optically it played directly into expected vitriolic fallout from advocates, activists and media touts, all of which lined up to ignite their “DEA should reschedule cannabis” torches. In a “perfect world” scenario these people aren’t wrong, cannabis isn’t Heroin’s equal & 1+1=2, but just as fire cannot exist in a vacuum, neither can a rational cannabis debate. And while everyone on the side of reason is shouting in unison about rescheduling they failed to see that they might have just had their pockets picked. DEA’s policy statement that everyone seemed to ignore there are 33 words that have the potential to create the legal framework for the monopolization of Cannabis by means of an exclusionary application process.

Prologue – August 10th, 2016

Russ Baer, a staff coordinator for the Drug Enforcement Administration (DEA) media affairs wing gave a response to Steven Nelson of USNEWS.com via email. Nelson later shared a screen grab of the email via tweet. The statement made to him from this Drug Enforcement Administration staff coordinator read:

“Tomorrow morning (August 11th, 2016) the Drug Enforcement Administration will be making some important announcement regarding Marijuana related topics that will be published in the Federal Register. Because of your interest and/or prior engagement with the DEA on this subject, the DEA office of National Media Affairs is reaching out to you regarding these anticipated announcements.”

Over the next 24 hours social media was a blaze, with many people within the industry uncovering the fact that Rescheduling wouldn’t happen and that the DEA response would have to do with research. As expected, the incendiary scheduling of cannabis debate raged on into the following day.

August 11th, 2016

As expected, the Drug Enforcement Administration disappointed the advocates and activists of medical marijuana by not removing or rescheduling marijuana from its class 1 controlled substance status. Yet the DEA, in all of its benevolence, offered a consolation prize of sorts, by “deciding” to expand the study of Medical Marijuana for researchers, Universities & drug companies outside of the confines of a single federally legal facility. The facility, to refresh your memory is located at the University of Mississippi, (ranked 164th in Bio Sciences) and had up to this point been the sole research monopoly on legally grown marijuana, courtesy of the NIDA (National Institute on Drug Abuse).

DEA’s Misdirection Strategy

Over the next few days it seemed that every headline following the DEA’s deliberation was about the archaic rescheduling system & how cannabis is safer statistically than opiates that are schedule 2. Some media outlets went as far as to paint a “glass half full” picture. The LA Times for example did a piece titled “DEA ends its monopoly on marijuana growing for medical research.” The social reaction from cannabis enthusiasts, advocates and potrepreneurs from Main Street to Wall Street was as expected with everyone chiming in on social media to wag their fingers at the DEA. Representative Barbara Lee, a congresswoman from Oakland California stating via tweet “Politicians aren’t doctors or scientists. Marijuana research prohibitions are outdated, unscientific, & dangerous for those who need #MMJ.” As expected the rhetoric from the cannabis side was “The DEA is bad, the War on Drugs is a complete failure, Big Pharma is to blame,” so on and so forth.

IMG_8473

The people aren’t wrong on many of these points. The War in Drugs is a failure when considering addiction has been plateauing since its 1970 inception and US drug control spending is up 2000%, which to date stands at $1.5 trillion dollars. We can go on and on as to where that money went, what industries it created (prison industrial complex), the people it disproportionately targeted (minorities), but that’s a whole other article or book for that matter. Big Pharma however does have its trillion dollars hands in this story, but more on that later as I’ve digressed.

Not to go back and pick on the LA Times click-bate headline of “DEA ends its monopoly on marijuana growing for medical research,” but did it really end the monopoly? Let’s evaluate the idea. Yes, a monopoly is defined as “the exclusive possession or control of the supply or trade in a commodity or service.” The University of Mississippi was in fact in exclusive possession of the NIDA edict to legally grow marijuana and study it. On the surface the Monopoly has ended, but the reality is that we are just switching out the term Monopoly for an Oligarchy. Is an oligarchy any different than a monopoly in the sense that it’s just a smaller group carving out the biggest slices for themselves, eliminating competition by means of out maneuvering or outspending their opponent in an effort to influence policy such as this? Consider that the biggest lobby against the cannabis Industry is the pharmaceutical industry, yet they’re simultaneously studying cannabis for the purpose of synthesizing its many chemical compounds to create their high margin drugs.

Currently, their high margin bread and butter are the opioids for pain management such as OxyContin, Percocet and their generic versions of each. The drug companies are experts at isolating molecules from nature to create drugs that cost pennies to manufactures. In a zero sum game, cannabis is a direct threat to pharma companies, by snatching billions in profit and simultaneously causing billions in losses. Anti-cannabis lobbies would also be at risk as the pharmaceutical giants that feed them down on K Street would lose out on easy paydays. These anti-Marijuana lobbyists provide a micro look at the systemic problems within American politics illustrating how/why elected officials in Congress consistently vote against the interests of their collective constituency and bring forth carefully crafted bills or amendments like this one.

On the DEA’s policy statement and legal considerations section, under, legal applicable considerations it states.

“Second, as with any application submitted pursuant to section 823(a), in determining whether the proposed registrationwould be consistent with the public interest, among the factorsto be considered are whether the applicant has previous experience handling controlled substances in a lawful manner and whether the applicant has engaged in illegal activity involving controlled substances. In this context, illegal activity includes any activity in violation of the CSA (regardless of whether such activity is permissible under State law) as well as activity in violation of State or local law. While past illegal conduct involving controlled substances does not automatically disqualify an applicant, it may weigh heavily against granting the registration.”

Translation, grow marijuana even in a state where it’s legal and you are going to have a hard time becoming a manufacturer or researcher for the DEA’s new policy, thus excluding tier one cultivators in practice and likely creating a perpetual home for cannabis on the scheduling list. Prohibition’s end could very well be right around the corner, but the fear is in the form of legal medical marijuana at a Walgreens near you. I asked the DEA’s Russ Baer directly if the inserted language above in bold would be a non-starter for current cultivators wanting to become manufacturers as they are in clear Violation of CSA? In a written statement to Marijuana Stocks the DEA’s official response was:

“DEA is serious about facilitating marijuana research and that there is a lawful pathway for doing so. This DEA decision will facilitate increased research involving marijuana, within the framework of the law and U.S. treaty obligations, to enhance the drug’s supply available to researchers. The goal of this historic and monumental policy shift is to increase the amount and variety of marijuana available to researchers and make it easier for researchers to obtain marijuana as compared to current system under which marijuana must be obtained from NIDA. Growers must become registered with DEA, following the submission of an application, which DEA will evaluate in accordance with the CSA. Registered growers will need to comply with all CSA regulatory requirements, such as quotas, record keeping, order forms, and maintenance of control against diversion. Marijuana produced under this proposal may only be supplied to DEA-registered manufacturers and researchers, and only for purposes authorized by the CSA.

All potential new drugs, including drug products made from marijuana, are subject to the rigors of the drug approval process mandated by the Federal Food, Drug and Cosmetic Act (FDCA). This drug approval process requires that before a new drug is allowed to enter the U.S. market, it must be demonstrated through sound clinical trials to be both safe and effective for its intended uses,” stated Russ Baer of the Drug Enforcement Agency.

When asked if the inserted language also creates an unfair advantage for Pharma companies the response from the Drug Enforcement Administration circled back to the CSA (Controlled Substance Act) stating that the “DEA has adopted a new policy, consistent with the CSA and U.S. treaty obligations, under which additional entities may become registered with DEA to grow and distribute marijuana for research purposes. DEA will evaluate each application it receives to determine whether adding such applicant to the list of registered growers is necessary to provide an adequate and uninterrupted supply of marijuana to researchers in the U.S. In addition, applicants must demonstrate their ability to safely secure the drugs to prevent diversion, while abiding by the approved research protocol.”

The Controlled Substance Act

Everything points back to the Controlled Substance Act, a bill that was introduced into the Congress by Harley Staggers and took less than 6 weeks to get passed by the Senate and signed into law by President Richard M. Nixon. The signing of this document not only created the “War on Drugs,” but put an enforcement agency (DEA) in charge of Cannabis scheduling, circumventing the FDA in a move that creates an inter-agency firewall of sorts. The DEA’s position on why the FDA, who already regulates pharmaceutical drugs, isn’t in charge of marijuana rescheduling was point blank, “The Controlled Substances Act provides a mechanism for substances to be controlled (added to or transferred between schedules) or decontrolled (removed from control). The CSA provides roles for DEA and the FDA. Proceedings to add, delete, or change the schedule of a drug or other substance may be initiated by DEA, HHS, or by petition from any interested party. Once initiated, the process involves a deliberate and collaborative interagency exchange.”

IMG_8472

In Laymen’s terms CSA effectively says “DEA you’re in charge of this, FDA you’re in charge of that.” Unfortunately, Marijuana will never be completely removed from the scheduling list unless there is a major political overhaul in every branch of government, if and only if elected officials stop letting lobbies pour honey in their ears and money into campaigns. The reality from my perspective is that the DEA is a scapegoat, the perfect Boogey Man, simply because their job is to follow orders. They are soldiers in a sense, adhering to the guidelines of the Controlled Substance Act (CSA), a legal document crafted by a congress, molded in the image of benefactors, used to fuel a fake war and create cottage industries.

The DEA knows marijuana is safer than Oxy and that’s not speculation that’s a direct quote. They don’t want to go after the mother transporting medication to her sick child because they’re suffering from seizures. They want the dangerous individuals like El Chapo or the pill mills slinging Oxy off the streets. They have no interest in going after all cultivators following state law to the letter. Are there exceptions, of course! Does it make these comments directly from them any less true? No.
DEA’s direct position on which drug is more dangerous from a consumption standpoint as it relates to Cannabis vs OxyContin? “There were more than 47,000 drug overdose deaths in 2014, or approximately 129 per day, more than half (61 percent) of which involved either a prescription opioid or heroin. Marijuana meets the statuary criteria of a Scheduled I controlled substance, and has been determined to have a high abuse potential with no currently accepted medical use. Schedule I includes some substances that are exceptionally dangerous (including heroin and LSD) and some that are less dangerous (including marijuana, which is less dangerous than some substances in other schedules).” When asked point blank, what’s more dangerous Oxy or Marijuana DEA says “Oxy.”

Robert Capecchi, Director of Federal Lobbying at the Marijuana Policy views medical marijuana legalization as a means to an opioid end as well as fiscal no brainer with far reaching benefits.

“Ending marijuana prohibition will allow licensed businesses to cultivate, distribute, and sell marijuana to adults. Unlike the criminal market, a legal and regulated market means products are pure, tested and labeled, sales are taxed, and business disputes are resolved in the courts, not with violence. Additionally, there is promising evidence to suggest that legal access to medical marijuana reduces the rates of opioid overdoses and the reliance on prescription pain killers.”

Foregone Conclusion?

Prohibition’s end could very well be right around the corner, but would we want it in the form of legal medical marijuana at a Walgreens near you? August 11th’s ruling was either one of many dominos in the quest for the monopolization of cannabis or just a pessimistic idea based off of history repeating itself. Regardless of which reality we are presently in, it doesn’t hurt to try and connect the dots, but if I can leave you with one last thing it’s the number 6630507. In case you’re wondering that’s the United States patent # they filed for cannabis in 2003 citing “multiple therapeutic uses.” I can only postulate why they did that….

Regards,

Jason Spatafora

Drug War

0 1483

Future Farm Closes on 15 Acres of Cannabis Zoned Land in Florida and Appoints John Sweeney as Chief Operating Officer

VANCOUVER, British Columbia, Feb. 8, 2017 /PRNewswire/ — Future Farm Technologies Inc. (the “Company” or “Future Farm”) (OTCQB: AGSTF) (CSE: FFT) is pleased to announce that it has closed on its previously announced definitive agreement to acquire a 15-acre parcel of land in Redland, Florida, in a county that is designated to legally cultivate, process and dispense cannabis. Redland is an unincorporated community within Miami-Dade County, with Biscayne National Park to the east and Everglades National Park to the west. Redland is primarily a Miami suburb and a major agricultural area. Miami-Dade County is referred to as the nation’s “Salad Bowl” and “Winter Bread Basket.”

“We are pleased to have reached this contract to acquire this prime parcel of land as it has a long history as a plant nursery, which was first established in 1963,” says Mr. William Gildea, Future Farm Technologies Inc.’s CEO and Chairman. Florida’s Legislature is beginning the process of figuring out how to implement Amendment 2, which allows for the expansion of legalized medical marijuana in Florida. The new law took effect on Tuesday, Jan. 3, 2017. The Florida Department of Health now has until June 3, 2017 to finalize its MMJ regulations and until September 3, 2017 to issue the first ID cards to patients. Amendment 2 was approved by 71 percent of Florida voters on Election Day, and will allow higher-strength marijuana to be used for a wider list of medical ailments.

With this acquisition, Future Farm has the potential, if fully licensed, to develop 15-acres of cannabis crops and is positioning itself to be a part of the Florida Cannabis market as it rolls out in 2017. If current state projections for the cannabis market size hold up to their $1.8B projection by 2020, Florida will have considerable demand for medical marijuana, even without factoring in the potential for recreational legislation.

This is an exciting acquisition for Future Farm as the 15-acre farm is located in a designated legal grow zone with close proximity to Miami. Future Farm is in a unique position as a Canadian based company because it is poised to quickly commence operations within the United States rather than potentially wait years to become a licensed producer under Canadian law.

Concurrent with this announcement, the Company is pleased to announce the appointment of John Sweeney as its Chief Operating Officer. Mr. Sweeney will transition into this executive position from his current role as a consultant and his big pharma background and expertise will help the Company capitalize on its current growth initiatives.

While serving as a consultant for the Company, Mr. Sweeney helped position the business firmly within the North American cannabis market through organic and inorganic growth initiatives. Going forward, Mr. Sweeney is going to play an important role in the next phase of the Company’s growth strategy.

Mr. Sweeney brings with him 16 years of direct cGMP (current Good Manufacturing Practices) manufacturing experience in operations of industry leading biotechnology companies including Pfizer, Wyeth, Genzyme and most recently as Vice President of Operations at Tilray, a 60,000-square foot federally licensed Canadian medical cannabis operation on Vancouver Island.

He has extensive knowledge and experience in the requirements of regulated manufacturing for commercial and clinical products and served as liaison for auditing regulatory agencies including the FDA and EMA. Mr. Sweeney holds an MS in Engineering Management from Tufts University in Medford, MA and a BS in Biology from the University of New Hampshire, Durham.

For further information, contact William Gildea, Director, at 617.834.9467.

On behalf of the Board,

Future Farm Technologies Inc.

William Gildea, CEO & Chairman

About Future Farm

The Company’s business model includes developing and acquiring technologies that will position it as a leader in the evolution of Controlled Environment Agriculture (CEA) for the global production of various types of plants. Future Farm provides scalable, indoor CEA systems that utilize minimal land, water and energy regardless of climate, location or time of year and are customized to grow an abundance of crops close to consumers, therefore minimizing food miles and its impact to the environment. The Company holds an exclusive, worldwide license to use a patented vertical farming technology that, when compared to traditional plant production methods, generate yields up to 10 times greater per square foot of land. The contained system provides many other benefits including seed to sale security, scalability, consistency due to year-round production, cost control, product safety and purity by eliminating environmental variability.

The Company is also in the business of designing and distributing LED lighting solutions utilizing the COB and MCOB technology. The Company is focused on delivering cost efficient lighting to North America via advanced e-commerce sites the Company owns and operates. LEDCanada.com which caters to B2B customers is a supplier of the newest and highest demand LED solutions. The Company also owns and operates COBGrowlights.com which caters to both large and small agriculture green houses and controlled cultivation centers.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

For further information, contact William Gildea, Director, at 617.834.9467.

2 2592

This morning Reliq Health Technologies (OTC:RQHTF) (TSX VENTURE:RHT) announced that through an MOU with Invictus MD Strategies Corp. (CSE:IMH)(OTC:IVITF) the company would be diving into the marijuana industry through the development of a mobile application for cannabis patients and consumers and their clinical care teams. Another clear example of how “Bio-tech” is beginning to carve its own space within the marijuana industry.

Reliq Health, a healthcare technology company focused on developing innovative mobile health and telemedicine solutions, has developed a novel SaaS (software as a service) solution for the community health care market. The solution provides automated remote patient monitoring in the home and secure cloud-based communication, care planning and collaboration for all members of the patient’s circle of care. Reliq’s secure platform allows clinicians to collect comprehensive data on patients’ clinical conditions, medication usage, symptoms, side effects and behaviours – creating a wealth of population health data.

“Studies consistently show that providing patients with the tools they need for self-management of their health conditions produces better health outcomes and reduces healthcare costs. Cannabis is prescribed to treat a wide range of conditions including arthritis, glaucoma, side effects from chemotherapy, chronic pain, multiple sclerosis and post-traumatic stress disorder.

Our cannabis app allows patients to track usage and record symptoms specific to their clinical condition, allowing patients and their care providers to determine optimum strain, dosing and mode of administration. Our platform will improve access to care by connecting patients with physicians in their community who have experience with medical marijuana, and supports physician-approved automated prescription refills through participating producers,” said Dr. Lisa Crossley, CEO of Reliq.

Invictus MD’s Chairman and CEO, Dan Kriznic, said, “Our wholly owned subsidiary: Poda Technologies Ltd. (“Poda“) is set for a launch in Q2 2017 of its Poda Pod vaporizer product which will provide an effective, reliable and convenient way to vaporize cannabis that is designed to appeal to modern retail and medical consumers.” The Poda Pod vaporizer product, made with medical-grade components, has been designed to connect to users’ smartphones via Bluetooth to provide real time information about dosage, product characteristics, track remaining contents, find vendors nearby, and customize their experience. Agreements are being negotiated to license the PODA products to the Access to Cannabis for Medical Purposes Regulations (“ACMPR“) and licensed producers in Canada, helping those producers better reach and serve consumers with convenient, refillable devices.

Mr. Kriznic added, “Invictus MD is excited and committed to working collaboratively with Reliq on this innovative mobile application to explore how Reliq’s solution can support Invictus’ commitment to its patients and consumers of cannabis products. Reliq’s technology platform will give Invictus the ability to collect relevant anonymized consumer data such as usage trends, frequency of usage and other relevant insights to improve the overall experience for medical marijuana patients.”

ON BEHALF OF THE BOARD
“Dr. Lisa Crossley”
CEO and Director

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statements Regarding Forward Looking Information
Certain statements in this press release constitute forward-looking statements, within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements”.

We caution you that such “forward-looking statements” involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements.

Forward-looking statements include, but are not limited to, statements with respect to commercial operations, including technology development, anticipated revenues, projected size of market, and other information that is based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management.

Reliq Health Technologies Inc. (the “Company”) does not intend, and does not assume any obligation, to update these forward-looking statements except as required by law. These forward-looking statements involve risks and uncertainties relating to, among other things, technology development and marketing activities, the Company’s historical experience with technology development, uninsured risks. Actual results may differ materially from those expressed or implied by such forward-looking statements.


Pursuant to an agreement between us and Reliq Health Technologies, Inc. we have been hired for a period of 30 days to publicly disseminate information about (RQHTF) including on the Website and other media including Facebook and Twitter. We are being paid $75,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (RQHTF), which we purchased in the open market. We plan to sell the “ZERO” shares of (RQHTF) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (RQHTF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

0 2330

mCig, Inc. (MCIG) continued to show strong growth on a quarter-over-quarter basis after the company reported preliminary results for the third quarter which ended on January 31st.

mCig has shown incremental growth following the company’s transition from a pure-play vaporizer company to a diversified holding company focused on the legal cannabis, hemp, and CBD markets as well as the picks & shovels approach with Greenhouse & other cultivation construction projects via their Scalable Solutions division.

Highlights from the company’s third quarter include:

● Generated $1.3 million in revenue (200% higher than the prior quarter) through its construction, CBD, and e-Cig divisions
● Reported $845,000 in net income (adjusted net income of $118,00), a company record
● Generated $341,000 in cash from operations and increased its cash, and cash equivalents to $420,000
● Reported to have more than $1.2 million in current assets with only $287,000 in current liabilities. This provides mCig with an acid test ratio of 4.3:1, its highest rating in company history.

The company’s success in the third quarter has brought total revenue for this fiscal year to $2.2 million. The revenue generated represents a 546% increase from the same period last year, and a 204% increase from last quarter.

MCIG’s net income during the quarter increased its total net income for the fiscal year to $716,000 (32% net profit margin).

From the Management Team

Michael Hawkins, Chief Financial Officer, stated, “For the third straight quarter MCIG has recorded record numbers. With its current contracts and booked revenue the Company will continue to see quarter over quarter growth in revenue.” He went on to say, “During this quarter we will revamp our segment reporting; changing from construction, wholesale, and retail; to construction, CBD, and e-Cig operations. We feel reporting on the segments under these new categories will provide a greater in depth review of our operations to our shareholders and investors.”

mCig CEO Paul Rosenberg said, “The cannabis industry is growing rapidly and MCIG has been there since the beginning. Management continues to focus on its business grow opportunities in Nevada, while continuing to service other states as well.”

A Trend to Watch

Over the last year, mCig has expanded its offering as well as the states it operates out of. The company recently entered its first business agreement in Maine which marked the sixth state the company is operating out of.
Investors should keep an eye on MCIG as this is a company to watch as they continue to expand their cultivation construction arm in the Nevada market, which we anticipate will become the most lucrative market outside of California. The continued execution coupled with a more attractive product and service line has made mCig an attractive partner for many businesses and we expect to see further expansion from here.

We may buy or sell additional shares of (MCIG) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER (http://marijuanastocks.com/content/terms-and-conditions-use/)

0 2328

Marijuana Stocks, Inauguration Day, & Trump’s Bump

Here we are, just after the official inauguration day of our 45th President of the United States of America, Donald Trump. A lot has been said about him over the last few years during the election race but what many may not have expected was a clear “Trump Bump” for marijuana stocks.


Click Here To View Full Article


 

Facts Regarding Denver’s New Marijuana In Public Law

Denver has begun working on the country’s first law allowing use in public places like coffee shops and cannabis clubs. However, the details about what those marijuana clubs would look like are still unclear. Here are some answers to questions about the cannabis clubs headed to Denver.


Click Here To View Full Article


 

Veterans In Support Of Medical Marijuana



Indiana American Legion reached an agreement on Sunday that would support a medical cannabis study to treat injuries to military service members, such as traumatic brain injuries and PTSD. The veteran service organization said they are working to urge Indiana legislators to approve the private growth and research of medicinal cannabis and to reclassify marijuana as a drug with potential medical value.


Click Here To View Article


 

 

 PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
Ad Placements